Press & News

People are different and so is their cancer, patients should be treated individually.

2cureX Newsletter May’21

May 12, 2021


Copenhagen, May 12th 2021

2cureX Newsletter #9

May’21 events at 2cureX: Successful Warrant exercise, Annual Report published, Investor presentations, AGM, new Analyst coverage and much more

Exercise of Warrants of the series TO1: 2cureX announced on May 11th that the exercise of warrants of series TO1 ended with high success. 96.75 % of the warrants were exercised, showing strong support from shareholders and bringing an injection of approximately SEK 31.4 million into 2cureX (view here).

2cureX’s Annual Report is published: On May 6th 2cureX published the 2020 Annual Report (download here). The report provides an overview of a very successful year for 2cureX and outlines the main focus areas of the company for 2021. The report will be presented for approval at the Annual General Meeting on May 26th.

Presentation at the RedEye Medtech & Diagnostics Seminar: On May 5th Fernando Andreu presented 2cureX and its market access plans at the RedEye Medtech & Diagnostics Seminar (view here). He provided an updated view of how Functional Testing can lead the next wave of Precision Oncology and how the company is building its leading position in that space.

New analyst Equity Report: On May 6th Mangold Insight issued a comprehensive report with a detailed analysis of 2cureX and the market we are addressing (download here). This is the first time Mangold covers 2cureX.

Annual General Meeting (AGM) will be held on May 27th: Due to the Corona-situation 2cureX BoD decided that the Annual General Meeting (view here) shall be held without a physical presence by shareholders exercising their voting rights by means of only advance voting, so-called postal voting.

Shareholder Q&A session will be held on May 28th: To compensate for the lack of physical presence at the Annual General Meeting, 2cureX invite our shareholders to participate in a live Q&A session on May 28th at 10:00. The Annual Report and plans going forward will be presented. Participants from 2cureX will be Povl-André Bendz (Chairman of the BoD), Fernando Andreu (CEO), Kenneth G. Johansen (CFO) and Ole Thastrup (CSO). Register here to participate.

Other upcoming events:

Life Science Investor Conference in Copenhagen on May 26, 2021 (link)

Redeye Growth Day 2021, Stockholm on June 2, 2021 (link)

Warmest Regards,

Fernando Andreu, CEO 2cureX